No products in the cart.
Pre-made Motavizumab benchmark antibody ( Whole mAb, anti-RSV gpF therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-357
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Motavizumab biosimilar, Whole Mab: Anti-RSV gpF therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Motavizumab (proposed INN, trade name Numax) is a humanized monoclonal antibody. It is being investigated by MedImmune (today a subsidiary of AstraZeneca) for the prevention of respiratory syncytial virus infection in high-risk infants. As of September 2009, it is undergoing Phase II and III clinical trials.
| Products Name (INN Index) | Pre-Made Motavizumab biosimilar, Whole Mab: Anti-RSV gpF therapeutic antibody |
|---|---|
| INN Name | Motavizumab |
| Target | RSV gpF |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Discontinued |
| 100% SI Structure | 3qwo:AB:HL/3ixt:HL:AB/4zyp:NO:JL:KM/6oe5:BC |
| 99% SI Structure | 5k8a:BA:FE:VM:HL/4jlr:AB:HL |
| 95-98% SI Structure | None |
| Year Proposed | 2006 |
| Year Recommended | 2007 |
| Companies | MedImmune |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Respiratory syncytial virus infections |
| Development Tech | Affinity Matured from Palivizumab |
| Previous Name | NA |
| Gm Offical Target Name | RSV gpF |
| Package |
Previous slide
Next slide
